Biogen drug shows signs of promise

NEW YORK — Biogen Idec Inc. said Thursday its longer-lasting injectable multiple sclerosis drug, peginterferon beta-1a, helped reduce patients’ risk of relapse by 36 percent when given every two weeks, meeting the goals of a late-stage study.

The medicine reduced patients’ risk of flare-ups by 28 percent when dosed every four weeks compared with placebo, the Weston, Mass., firm said in a statement. Based on the results, Biogen said it plans to apply this year for regulatory approval in Europe and the United States.


Peginterferon is a version of Biogen’s best-selling drug, Avonex, which is given by injection once a week. Avonex generated $2.7 billion in 2011 revenue. The longer-lasting drug would be deemed successful if it reduced the risk of relapse by at least 30 percent, said Michael Yee, an analyst with RBC Capital Markets.

The trial of more than 1,500 patients was part of the third and final stage of studies generally required for US approval. The drug was safe and tolerable across different dosing frequencies, Biogen said. The most common side effects were redness at the injection site and flu-like symptoms.

Bloomberg News

Loading comments...
Real journalists. Real journalism. Subscribe to The Boston Globe today.
You're reading  1 of 5 free articles.
Get UNLIMITED access for only 99¢ per week Subscribe Now >
You're reading1 of 5 free articles.Keep scrolling to see more articles recomended for you Subscribe now
We hope you've enjoyed your 5 free articles.
Continue reading by subscribing to for just 99¢.
 Already a member? Log in Home
Subscriber Log In

We hope you've enjoyed your 5 free articles'

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of
Marketing image of